5VT0 Stock Overview A clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
vTv Therapeutics Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for vTv Therapeutics Historical stock prices Current Share Price US$13.00 52 Week High US$26.40 52 Week Low US$11.60 Beta 0.68 1 Month Change -11.56% 3 Month Change -0.76% 1 Year Change n/a 3 Year Change -58.49% 5 Year Change -80.99% Change since IPO -96.38%
Recent News & Updates
New minor risk - Shareholder dilution Aug 26
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold Jul 27
New minor risk - Shareholder dilution Jul 22
New minor risk - Shareholder dilution Jul 20
vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes Jun 25
New minor risk - Shareholder dilution Jun 13 See more updates
New minor risk - Shareholder dilution Aug 26
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold Jul 27
New minor risk - Shareholder dilution Jul 22
New minor risk - Shareholder dilution Jul 20
vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes Jun 25
New minor risk - Shareholder dilution Jun 13
New minor risk - Shareholder dilution Jun 11
New minor risk - Shareholder dilution Jun 10
High number of new and inexperienced directors May 22
vTv Therapeutics Inc., Annual General Meeting, Jun 11, 2024 May 01 vTv Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $12.678712 million. Apr 30
vTv Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $12.678712 million. Apr 11
vTv Therapeutics Inc. Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes Mar 05
vTv Therapeutics Inc. Announces Board Changes Mar 01 vTv Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $4.923802 million.
Vtv Therapeutics Inc. Announces Resignation of Chandresh Harjivan as Member of the Board of Directors Dec 23
vTv Therapeutics Receives Non-Compliance Notice From Nasdaq Dec 20
Vtv Therapeutics Inc. Appoints Thomas Strack, M.D., as Chief Medical Officer Nov 03
New major risk - Share price stability Aug 24
New major risk - Negative shareholders equity Aug 14
First half 2023 earnings released: US$0.12 loss per share (vs US$0.15 loss in 1H 2022) Aug 13
Nasdaq Approves vTv Therapeutics' Request to Extend the Period to Regain Compliance with the Minimum Bid Requirement Until December 18, 2023 Jul 23
First quarter 2023 earnings released: US$0.055 loss per share (vs US$0.10 loss in 1Q 2022) May 13
vTv Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023 May 12
Full year 2022 earnings released: US$0.26 loss per share (vs US$0.21 loss in FY 2021) Mar 08
vTv Therapeutics Inc. Appoints Elizabeth Keiley as Executive Vice President and General Counsel Feb 02
vTv Therapeutics Receives a Letter from NASDAQ Regarding Minimum Bid Price Dec 26
vTv Therapeutics Inc. Appoints Steven Tuch as Chief Financial Officer Dec 14
Third quarter 2022 earnings released: US$0.053 loss per share (vs US$0.018 loss in 3Q 2021) Nov 16
High number of new directors Nov 16
Third quarter 2022 earnings released: US$0.053 loss per share (vs US$0.018 loss in 3Q 2021) Nov 13
Second quarter 2022 earnings released: US$0.045 loss per share (vs US$0.01 loss in 2Q 2021) Aug 17
vTv Therapeutics Inc. Appoints Jonathan Isaacsohn as Member and Chair of the Board Aug 17
High number of new directors Aug 02 vTv Therapeutics Inc. Announces CEO Changes
Jon Isaacsohn to Join the vTv Therapeutics Inc. Board of Directors Jul 26
vTv Therapeutics Inc. Announces Executive Changes Jul 17 vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes vTv Therapeutics Inc. announced that it expects to receive $24.999762 million in funding from G42 Investments Ai Holding Rsc Ltd Jun 02
First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.075 loss in 1Q 2021) May 13
vTv Therapeutics Inc., Annual General Meeting, Jun 01, 2022 May 03
Robin E. Abrams Resigns as Executive Chairperson of the Board of Directors of vTv Therapeutics Inc Apr 16
vTv Therapeutics Inc. Announces Not to Stand for Re-Election of Noel Spiegel as Director and Chair of the Audit Committee of the Board Apr 06
Full year 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in FY 2020) Mar 31 vTv Therapeutics Inc. Announces Executive Changes
vTv Therapeutics Inc. Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis Sep 24 vTv Therapeutics Inc.(NasdaqCM:VTVT) dropped from Russell 3000E Index
First quarter 2021 earnings released: US$0.075 loss per share (vs US$0.11 loss in 1Q 2020) May 06 vTv Therapeutics Inc. Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes
Director recently bought €142k worth of stock Mar 03
Full year 2020 earnings released: US$0.18 loss per share (vs US$0.59 loss in FY 2019) Feb 26
Revenue beats expectations Feb 26
vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes Feb 24
vTv Therapeutics Inc. Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis Feb 18
vTv Therapeutics Inc. Announces Executive Changes Dec 31 vTv Therapeutics Announces Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes
New 90-day high: €1.83 Dec 11
vTv Therapeutics Inc. Appoints Rich Nelson as A Member of the Board Nov 18
Revenue in line with expectations Nov 07
vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study Nov 06
Edward P. Taibi Resigns from the Board of Directors of vTv Therapeutics, Inc Oct 03
vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes Sep 24 Shareholder Returns 5VT0 DE Biotechs DE Market 7D 1.6% 2.5% -0.4% 1Y n/a -10.2% 7.9%
See full shareholder returns
Return vs Market: Insufficient data to determine how 5VT0 performed against the German Market .
Price Volatility Is 5VT0's price volatile compared to industry and market? 5VT0 volatility 5VT0 Average Weekly Movement 10.8% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 5VT0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5VT0's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company’s lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention.
Show more vTv Therapeutics Inc. Fundamentals Summary How do vTv Therapeutics's earnings and revenue compare to its market cap? 5VT0 fundamental statistics Market cap €45.44m Earnings (TTM ) -€17.76m Revenue (TTM ) €970.40k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 5VT0 income statement (TTM ) Revenue US$1.00m Cost of Revenue US$11.45m Gross Profit -US$10.45m Other Expenses US$7.86m Earnings -US$18.31m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -7.01 Gross Margin -1,045.00% Net Profit Margin -1,830.60% Debt/Equity Ratio 0%
How did 5VT0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/05 18:11 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources vTv Therapeutics Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners Corey Davis Canaccord Genuity Charles Duncan Cantor Fitzgerald & Co.
Show 7 more analysts 
